Trial reportBlood2018
α
Open access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
9.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 110 citations in OpenAlex.
- Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease.Transplantation and cellular therapy · 2023Trial
- Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin.Blood advances · 2020Trial
- Trial
- A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.Blood advances · 2020Trial
- 99mTc-HSA scintigraphy identifies protein-losing enteropathy in atypical GI-GVHD with modest diarrhea after allo-HSCT.International journal of hematology · 2026Article
- System-level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated With High One-year Survival and Reduced Cost.Transplantation and cellular therapy · 2026Article
- Alpha 1 Antitrypsin Suppresses Autoantibody Production and Cellular Autoimmunity in Chronic Graft-Versus-Host Disease (cGVHD) in a Lupus Mouse Model.Biomolecules · 2026Article
- Mammalian target of rapamycin inhibitors as the treatment for steroid-refractory acute graft-vs.-host disease after allogeneic hematopoietic stem cell transplantation: A systematic review and individual patient data meta-analysis.Experimental and therapeutic medicine · 2026Article
- [Advances in the prevention and treatment of acute graft-versus-host disease with cellular and novel targeted immunotherapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Review
- Evaluation of cyclophosphamide for steroid-refractory hepatic acute graft-vs-host disease after allogeneic hematopoietic stem cell transplantation.Frontiers in immunology · 2026Article
- Gastrointestinal acute graft versus host disease: a translational perspective from pathogenesis to precision prevention and treatment.Frontiers in immunology · 2026Review
- New age GVHD prophylaxis regimens: what works for what donor and why.Hematology. American Society of Hematology. Education Program · 2025Review
- Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC.Blood advances · 2025Article
- Bioanalytical Method Validations of Three Alpha1-Antitrypsin Measurement Methods Required for Clinical Sample Analysis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Clinical Study Support by Long-Term Stability Studies of AlphaPharmaceuticals (Basel, Switzerland) · 2025Article
- Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Biochemical markers and emerging therapies for intestinal manifestation of graft-versus-host disease.Frontiers in immunology · 2025Review
- Modern-Era Challenges in the Clinical Management of Graft-Versus-Host Disease.Advances in experimental medicine and biology · 2025Review
- Editorial: Allogenic hematopoietic cell transplant in hematological malignancies: controversies and perspective.Frontiers in oncology · 2025Article
- The Inhibitory Effects of Alpha 1 Antitrypsin on Endosomal TLR Signaling Pathways.Biomolecules · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 2 countries.
John M MagenauBlood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
Steven C GoldsteinBlood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
Dan PeltierBlood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
Robert J SoifferStem Cell/Bone Marrow Transplantation Program, Division of Hematologic Malignancy, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Thomas BraunDepartment of Biostatistics, University of Michigan, Ann Arbor, MI.
Attaphol PawarodeBlood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
Mary M RiwesBlood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
Maggi KennelBlood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
Joseph H AntinStem Cell/Bone Marrow Transplantation Program, Division of Hematologic Malignancy, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Corey S CutlerStem Cell/Bone Marrow Transplantation Program, Division of Hematologic Malignancy, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Vincent T HoStem Cell/Bone Marrow Transplantation Program, Division of Hematologic Malignancy, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Edwin P AlyeaStem Cell/Bone Marrow Transplantation Program, Division of Hematologic Malignancy, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Brian L ParkinBlood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
Gregory A YanikBlood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
Sung Won ChoiBlood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
Eli C LewisDepartment of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva, Israel; and.
Charles A DinarelloDepartment Medicine and Immunology, University of Colorado, Aurora, CO.
John KorethStem Cell/Bone Marrow Transplantation Program, Division of Hematologic Malignancy, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Pavan ReddyBlood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.ORCID 0000-0001-7264-8429
University of Michigan · USHarvard University · USBen-Gurion University of the Negev · ILUniversity of Colorado Anschutz Medical Campus · US
Funding
Training Program in Molecular HematologyT32HL007622 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SUNG WON CHOI, Jordan A. Shavit · 1986 to 2026
$9.2MAdvancing Child Health Through Cellular and Molecular BiologyK12HD028820 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Donna M. Martin · 2002 to 2026
$9.2MYeast-based HTS Assay Technologies for ProteasesR01AI015614 · NIAID · UNIVERSITY OF COLORADO DENVER · PI DINARELLO, CHARLES ANTHONY · 1985 to 2025
$8.5MCellular and molecular mechanisms of target tissue resistance for mitigating GVHD severityR01CA203542 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI REDDY, PAVAN · 2016 to 2020
$2.4MDevelopment of novel strategy for treatment of steroid refractory GVHDR01HL128046 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI REDDY, PAVAN · 2015 to 2019
$2.1MRole of noncoding RNA in Regulating GVHDR01CA173878 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI REDDY, PAVAN · 2013 to 2017
$1.6MTargeting antigen cross-presentation to enhance anti-leukemic responses after allogeneic transplantationK23AI123595 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MAGENAU, JOHN MARTIN · 2017 to 2021
$983kPathogenesis of Fever in ManR56AI015614 · NIAID · UNIVERSITY OF COLORADO DENVER · PI DINARELLO, CHARLES ANTHONY · 2016 to 2016
$311kNCI NIH HHS R01 CA173878NCI NIH HHS R01 CA203542NHLBI NIH HHS R01 HL128046NHLBI NIH HHS T32 HL007622NIAID NIH HHS K23 AI123595NIAID NIH HHS R01 AI015614NIAID NIH HHS R56 AI015614NICHD NIH HHS K12 HD028820
Abstract
Corticosteroid resistance after acute graft-versus-host disease (SR-aGVHD) results in high morbidity and mortality after allogeneic hematopoietic cell transplantation. Current immunosuppressive therapies for SR-aGVHD provide marginal effectiveness because of poor response or excessive toxicity, primarily from infection. α
Indexed as
alpha 1-AntitrypsinGraft vs Host DiseaseAcute DiseaseAdministration, IntravenousAdultDisease-Free SurvivalFemaleHumansInfectionsMaleMiddle AgedProspective StudiesSurvival Ratealpha 1-Antitrypsin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.